| |
|
|
|
-, Mandalay Bay Resort & Casino, Las Vegas, NV
April 25-29, 2004
Learn how to accelerate your drug development program and to optimize your manufacturing operations with inside information from industry leaders at TIDES® 2004: IBC’s Oligonucleotide and Peptide Technology Conferences – the most widely praised and well attended event specifically designed for manufacturing and drug development scientists. TIDES® 2004 will discuss leading clinical candidates on Riquent™, Genasense™, Macugen™, and Plenaxis™; strategies and case studies on manufacturing, development, and regulatory; applications of therapeutics, diagnostics, and research; latest delivery technologies of oral, nasal, polymer, cell, and SiRNA; updates on compounds in development; and an inside look into the Aventis/Genta Collaboration. Hear in-depth keynote presentations on Plenaxis™: From Peptide to Approved Pharmaceutical from Malcolm L. Gefter, Ph.D., Praecis Pharmaceuticals Incorporated & Development of Genasense™ for Cancer Therapy from Robert E. Klem, Ph.D., Genta Incorporated. For up-to-date information on this event and to register online, visit www.LifeSciencesInfo.com/TIDES.
|
|
|
|
|
|
|
|
Organized by:
|
|
IBC Life Sciences |
|
|
Invited Speakers:
|
|
Keynote Presenters "Plenaxis(TM): From Peptide to Approved Pharmaceutical"
- Malcolm L. Gefter, Ph.D., Chairman and CEO, Praecis Pharmaceuticals Incorporated "Development of Genasense(TM) for Cancer Therapy"
- Robert E. Klem, Ph.D., Formerly Head of RD & Manufacturing/Retired, Genta Incorporated
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
-
|
|
|
|
|
|
|
|
Registration:
|
|
Phone: 508) 616-5550 x1004
Fax: (508) 616-5522
Email: reg@ibcusa.com
Online: www.LifeSciencesInfo.com/TIDES
|
|
|
E-mail:
|
|
reg@ibcusa.com
|
|
|
|
|
|
|
|
|